title: Soluble CD23 in human immunodeficiency virus type 1 infected patients.
abstract: The level of sCD23 produced in the course of human immunodeficiency virus (HIV) infection was measured in patients grouped according to the Centers for Disease Control by using an immunoradiometric assay. Soluble CD23 was evaluated in supernatants of peripheral blood mononuclear cell (PBMC) (10(6) cells/ml) stimulated by phytohemagglutinin (PHA). Compared with healthy controls (m +/- S.D. = 1.0 +/- 0.34 U/ml, n = 7), higher values were observed in some of the patients of group II (asymptomatic) (m +/- S.D. = 2 +/- 1.33, n = 9) and some of the patients of group IV (AIDS) (m +/- S.D. = 1.3 +/- 1.40, n = 8). Those results prompted us to compare the plasma levels of sCD23 in group II and group IV HIV-infected patients and in healthy individuals. Soluble CD23 plasma levels in healthy patients (n = 42) ranged from 0 to 1.5 U/ml (m +/- S.D. = 0.9 +/- 0.33), in group II patients (n = 17) from 0 to 3 U/ml (m +/- S.D. = 0.92 +/- 0.83) and in group IV patients (n = 73) from 0 to 2.9 U/ml (m +/- S.D. = 1.15 +/- 0.71). The differences between the patients and the healthy individuals were not statistically significant but individual sCD23 values higher than 2 U/ml were obtained in 6% of the group II patients and 16.7% of the group IV patients. Increased values of sCD23 were obtained in plasma from patients with secondary infectious diseases (groups IV-Cl and IV-C2) and from patients without secondary infectious diseases (group II, group IV-A and group IV-B).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Service de Bactériologie-virologie B, CHRU Lille, France.
authors.forename: D
authors.initials: D
authors.lastname: Hober
authors.forename: F
authors.initials: F
authors.lastname: Ajana
authors.forename: M
authors.initials: M
authors.lastname: Boniface
authors.forename: R
authors.initials: R
authors.lastname: Estrada
authors.forename: P E
authors.initials: PE
authors.lastname: Lobert
authors.forename: C
authors.initials: C
authors.lastname: Sartiaux
authors.forename: Y
authors.initials: Y
authors.lastname: Mouton
authors.forename: P
authors.initials: P
authors.lastname: Wattré
authors.forename: M
authors.initials: M
authors.lastname: Maniez-Montreuil
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000473:pathology; D002478:Cells, Cultured; D004797:Enzyme-Linked Immunosorbent Assay; D015658:HIV Infections / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D015592:Immunoradiometric Assay; D007958:Leukocyte Count; D008213:Lymphocyte Activation / Q000276:immunology; D010835:Phytohemagglutinins; D017455:Receptors, IgE / Q000032:analysis* / Q000096:biosynthesis; D012995:Solubility; D050378:T-Lymphocytes, Regulatory / Q000276:immunology / Q000473:pathology
chemical_list: D010835:Phytohemagglutinins; D017455:Receptors, IgE